AU2001287157A1 - Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents - Google Patents
Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agentsInfo
- Publication number
- AU2001287157A1 AU2001287157A1 AU2001287157A AU8715701A AU2001287157A1 AU 2001287157 A1 AU2001287157 A1 AU 2001287157A1 AU 2001287157 A AU2001287157 A AU 2001287157A AU 8715701 A AU8715701 A AU 8715701A AU 2001287157 A1 AU2001287157 A1 AU 2001287157A1
- Authority
- AU
- Australia
- Prior art keywords
- adoptosis
- promotion
- administration
- cancer cells
- kinase inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000024245 cell differentiation Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000011260 co-administration Methods 0.000 title 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 title 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23188500P | 2000-09-12 | 2000-09-12 | |
| US60231885 | 2000-09-12 | ||
| PCT/US2001/028297 WO2002022133A1 (en) | 2000-09-12 | 2001-09-07 | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001287157A1 true AU2001287157A1 (en) | 2002-03-26 |
Family
ID=22871001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001287157A Abandoned AU2001287157A1 (en) | 2000-09-12 | 2001-09-07 | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20050004007A1 (en) |
| AU (1) | AU2001287157A1 (en) |
| WO (1) | WO2002022133A1 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102480D0 (en) * | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
| DK3351246T3 (en) * | 2001-02-19 | 2019-06-03 | Novartis Pharma Ag | Rapamycin derivatives for the treatment of a solid tumor associated with deregulated angiogenesis |
| WO2003032921A2 (en) * | 2001-10-16 | 2003-04-24 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| CA2476434A1 (en) * | 2002-02-15 | 2003-08-28 | Sloan-Kettering Institute For Cancer Research | Method of treating trx mediated diseases |
| US20070060614A1 (en) * | 2002-03-04 | 2007-03-15 | Bacopoulos Nicholas G | Methods of treating cancer with hdac inhibitors |
| US20040072735A1 (en) * | 2002-03-04 | 2004-04-15 | Richon Victoria M. | Methods of inducing terminal differentiation |
| US20060276547A1 (en) * | 2002-03-04 | 2006-12-07 | Bacopoulos Nicholas G | Methods of treating cancer with HDAC inhibitors |
| US7148257B2 (en) * | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7456219B2 (en) * | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| IL164599A0 (en) * | 2002-04-15 | 2005-12-18 | Sloan Kettering Inst Cancer | Combination therapy for the treatment of cancer |
| EP1572083A4 (en) | 2002-04-25 | 2008-09-24 | Univ Connecticut Health Ct | USE OF HEAT SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC UTILIZATION OF A TREATMENT MODALITY WITHOUT VACCINE |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20070060615A1 (en) * | 2003-02-18 | 2007-03-15 | University Of South Florida | Method of Modulating Apoptosis Through Modulation of E2F1 |
| US7381825B2 (en) | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| GB0315259D0 (en) * | 2003-06-30 | 2003-08-06 | Cyclacel Ltd | Use |
| DK1663194T3 (en) * | 2003-08-26 | 2010-07-19 | Merck Hdac Res Llc | Use of SAHA to treat mesothelioma |
| CN101856348A (en) * | 2003-08-29 | 2010-10-13 | 斯隆-凯特林癌症研究所 | Combination Approaches to Treating Cancer |
| US20070287718A1 (en) * | 2003-11-06 | 2007-12-13 | Green Simon R | Methods for the Treatment of Multiple Myeloma Using Roscovitine |
| US7642275B2 (en) | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1896436A2 (en) | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1942907A2 (en) * | 2005-11-04 | 2008-07-16 | Merck and Co., Inc. | Methods of using saha and erlotinib for treating cancer |
| EP1947936A4 (en) * | 2005-11-04 | 2010-02-10 | Merck & Co Inc | Methods of using saha and bortezomib for treating cancer |
| EP1951307A2 (en) * | 2005-11-11 | 2008-08-06 | Cyclacel Limited | Combination of a cdk-inhibitor and a hdac-inhibitor |
| GB0523040D0 (en) * | 2005-11-11 | 2005-12-21 | Cyclacel Ltd | Combination |
| WO2008057456A2 (en) * | 2006-11-03 | 2008-05-15 | University Of Maryland, Baltimore | Methods of using saha and bortezomib for treating multiple myeloma |
| WO2010036404A2 (en) * | 2008-05-09 | 2010-04-01 | University Of Maryland, Baltimore | Novel retinamide retinoic acid metabolism blocking agents |
| US20130005747A1 (en) * | 2010-12-21 | 2013-01-03 | Cyclacel Limited | Method for selecting a cancer therapy |
| MX2018006250A (en) | 2015-11-18 | 2018-09-05 | Genzyme Corp | BIOMARCADOR OF POLIQUISTIC RENAL DISEASE AND USES OF THE SAME. |
| AU2017315357B2 (en) | 2016-08-23 | 2022-12-01 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
| MA47776A (en) | 2017-03-16 | 2020-01-22 | Eisai R&D Man Co Ltd | POLYTHERAPIES FOR THE TREATMENT OF BREAST CANCER |
| CA3060243A1 (en) | 2017-04-17 | 2018-10-25 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5880152A (en) * | 1995-10-06 | 1999-03-09 | Vertex Pharmaceuticals, Inc. | Butyrate prodrugs derived from lactic acid |
| US5821072A (en) * | 1996-02-20 | 1998-10-13 | Sloan-Kettering Institute For Cancer Research | Combinations of PKC inhibitors and therapaeutic agents for treating cancers |
| US6060505A (en) * | 1996-03-20 | 2000-05-09 | The United States Of America As Represented By The Department Of Health And Human Services | Method of treating cancer using C-26 modified bryostatin |
| US6211239B1 (en) * | 1996-07-17 | 2001-04-03 | Centre International De Recherches Dermatologiques Galderma | Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN) |
| US6034074A (en) * | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US5922571A (en) * | 1997-03-06 | 1999-07-13 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a protein kinase C homolog |
| US6262116B1 (en) * | 1998-01-23 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Transcription therapy for cancers |
| US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
| US6509315B1 (en) * | 2000-04-07 | 2003-01-21 | The Trustees Of The University Of Pennsylvania | Didemnin analogs and fragments and methods of making and using them |
| US20020016293A1 (en) * | 2000-04-21 | 2002-02-07 | Ratain Mark J. | Flavopiridol drug combinations and methods with reduced side effects |
-
2001
- 2001-09-07 WO PCT/US2001/028297 patent/WO2002022133A1/en active Application Filing
- 2001-09-07 US US10/363,540 patent/US20050004007A1/en not_active Abandoned
- 2001-09-07 AU AU2001287157A patent/AU2001287157A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002022133A1 (en) | 2002-03-21 |
| US20050004007A1 (en) | 2005-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001287157A1 (en) | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents | |
| AU2001270260A1 (en) | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors | |
| AU2001278070A1 (en) | Basal cell markers in breast cancer and uses thereof | |
| AU2001259758A1 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
| AU2003284242A1 (en) | Methods and compositions for use in treating cancer | |
| AU2002227300A1 (en) | Reducing cellular damage in the human body | |
| IL156131A0 (en) | Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors | |
| AU2001244355A1 (en) | Heterobiarylsulphonamides and their use as pde 7 inhibitors | |
| AU2003256410A1 (en) | COMBINATION THERAPY WITH p38 MAP KINASE INHIBITORS AND THEIR PHARMACEUTICAL COMPOSITIONS | |
| AU2002252731A1 (en) | Compositions and methods of double-targeting virus infections and cancer cells | |
| AU2002315168A1 (en) | Combination therapy of gamma-interferon and b cell specific antibodies | |
| AU5066900A (en) | Benzimidazole derivatives and their use as methionyl t-rna synthetase inhibitors | |
| AU2003298937A1 (en) | Heterocyclic compounds, methods of making them and their use in therapy | |
| AU4642600A (en) | Methods and compositions for use in potentiating antigen presentation by antigenpresenting cells | |
| AU1453301A (en) | Methods of reversing drug resistance in cancer cells | |
| AU2001258381A1 (en) | Use of parp inhibitors in cosmetic preparations | |
| AU2001271266A1 (en) | Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes | |
| AU2002256347A1 (en) | Compositions and methods for the identification of protein interactions in vertebrate cells | |
| AU2002356898A1 (en) | Gene amplification and overexpression in cancer | |
| AU2000237154A1 (en) | Method for detecting and killing epithelial cancer cells | |
| AU2881301A (en) | Cancer cell implantation inhibitors | |
| AU2003257043A1 (en) | Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors | |
| AU2001255696A1 (en) | Telomerase inhibitors and methods of their use | |
| AU2001288219A1 (en) | Stimulation of cellular regeneration and differentiation in the inner ear | |
| AU2001240025A1 (en) | Cell cycle proteins associated with rad9, compositions and methods of use |